Name change to Talphera reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings
Talphera will begin trading on Nasdaq.
Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter.